Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...

Photodisinfection technology could be a game-changer in fight against antimicrobial resistance Vancouver, Canada, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant...